Misplaced Pages

Foravirumab: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 10:44, 31 October 2011 editBeetstra (talk \| contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'CAS_number').← Previous edit		Revision as of 10:44, 31 October 2011 edit undoBeetstra (talk \| contribs)Edit filter managers, Administrators172,031 edits Script assisted update of identifiers for the Chem/Drugbox validation project (updated: '').Next edit →
Line 33:		Line 33:
	\| ChemSpiderID = NA		\| ChemSpiderID = NA
	\| CAS_number_Ref = {{cascite\|correct\|??}}		\| CAS_number_Ref = {{cascite\|correct\|??}}
	\| CAS_number = ~~<!-- blanked - oldvalue:~~ 944548-38-3 ~~-->~~		\| CAS_number = 944548-38-3
	\| ATC_prefix = none		\| ATC_prefix = none
	\| ATC_suffix =		\| ATC_suffix =

Revision as of 10:44, 31 October 2011

Pharmaceutical compound

Foravirumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	rabies virus glycoprotein
Clinical data
ATC code	none
Identifiers
CAS Number	944548-38-3
ChemSpider	NA
UNII	377VY97V7S
Chemical and physical data
Formula	C₆₄₀₀H₉₉₁₄N₁₇₁₈O₁₉₉₈S₄₄
Molar mass	144.3 kDa g·mol
(what is this?) (verify)

Foravirumab is a monoclonal antibody for the prophylaxis of rabies.

References

International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.

v
t
e

Monoclonal antibodies for infectious disease and toxins

Human	Efungumab

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab Bamlanivimab (+etesevimab) Bebtelovimab Casirivimab (+imdevimab) Cilgavimab (+tixagevimab) Diridavumab Etesevimab Exbivirumab Foravirumab Imdevimab (+casirivimab) Libivirumab Maftivimab Nirsevimab Odesivimab Pemivibart Rafivirumab Regavirumab Regdanvimab Sevirumab Sipavibart Sotrovimab Suptavumab Tixagevimab (+cilgavimab) Tuvirumab
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab
Humanized	Felvizumab Lenvervimab Motavizumab Palivizumab Suvizumab

Human	Nebacumab Panobacumab Raxibacumab
Mouse	Edobacomab
Chimeric	Pagibaximab
Humanized	Tefibazumab

Human	Actoxumab Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

v
t
e

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

v
t
e